EuroPCR: Medtronic renal denervation system shows better blood pressure control with significantly more time in target range

Medtronic adds to SPYRAL HTN Global Clinical Program with late breaking clinical data for SPYRAL HTN-ON MED and GSR-DEFINE

Medtronic plc (NYSE: MDT), a global leader in healthcare technology, today announced data showing the benefits of the Symplicity Blood Pressure Procedure with the Symplicity Spyral™ Renal Denervation (RDN) system on achieving target blood pressure level ranges. As part of the SPYRAL HTN Global Clinical Program, three-year data from SPYRAL HTN-ON MED and GSR-DEFINE were presented at EuroPCR 2022 as late-breaking clinical trials on May 17, 2022.

Time in target range (TTR) plays an important role in the management of many chronic diseases, such as diabetes and hypertension, measuring how well a parameter (e.g., blood pressure) is controlled in patients. Specifically, for hypertension, increasing TTR has been shown to be an independent predictor of reductions in cardiovascular risks, including stroke, heart attack, and death. 1 In a recent consensus statement by the Society for Cardiovascular Angiography & Interventions and the National Kidney Foundation, TTR is recognized as an effective measure of blood pressure control. As part of the statement, TTR is also noted as an important consideration to include as an endpoint in clinical trials and registries.

"The data presented today at EuroPCR provide meaningful insights into the benefits of RDN through a patient lens, looking at how much time they spend within a target BP range," said Jason Weidman , senior vice president and president of the Coronary & Renal Denervation business, which is part of the Cardiovascular Portfolio at Medtronic. "This new data reinforces RDN's effectiveness as a complementary solution for achieving better blood pressure control and reducing cardiovascular risk."

Results from the first 80 patients in the SPYRAL HTN-ON MED trial demonstrate improved BP control with significantly higher TTR after radiofrequency RDN when compared to sham through three years, regardless of anti-hypertensive medications. TTR for patients treated with RDN (33.7% TTR) was nearly double of sham patients (18.8% TTR) through three years (p=0.023).

SPYRAL HTN-ON MED is a global, randomized, sham-controlled trial investigating the blood pressure lowering effect and safety of RDN with the radiofrequency-based Medtronic Symplicity Spyral system in hypertensive patients prescribed one to three anti-hypertensive medications. The trial enrolled 80 typical uncontrolled hypertensive patients, randomized to RDN (n=38) or sham control (n=42).

The findings build upon the recent three-year safety and efficiency data presented at ACC.22 , which demonstrated safe and sustained blood pressure reductions through three years.

"By focusing on TTR in patients with uncontrolled hypertension, we can better understand how RDN can help control blood pressure and sustain a healthy level," said Dr. David Kandzari , chief, Piedmont Heart Institute and Cardiovascular Services and SPYRAL HTN-ON MED lead principal investigator. "These three-year data showed us that RDN nearly doubles the time patients spend in their target blood pressure range, regardless of anti-hypertensive medications, reinforcing the long-term benefit of the procedure."

GSR-DEFINE 3-Year Data
In the GSR-DEFINE study, improved blood pressure control after radiofrequency RDN is associated with lower risk of major adverse cardiovascular events (MACE) through three years in real-world patients. RDN patients spent 34.9% time in TTR through three years. There was also a 16% decrease in MACE associated with every 10% increase in TTR at 6 months.

GSR-DEFINE is a prospective, all-comer observational study in 222 sites across 42 countries, including 3,000 patients from the GSR study and enrolling up to an additional 2,000 patients.

"Results from this real-world patient setting closely mirror and build upon data from the SPYRAL HTN-ON MED trial showing improved blood pressure control with RDN. The findings from GSR-DEFINE further underscore the long-term safety and effectiveness of the Symplicity system in patients with uncontrolled hypertension, while also lowering their risk of major cardiovascular events," said Prof. Felix Mahfoud , M.D., cardiologist at Saarland University Hospital in Homburg, Germany , and member of the SPYRAL HTN executive committee.

About the Medtronic Symplicity Spyral™ Renal Denervation System
The Medtronic RDN procedure uses a minimally invasive procedure that delivers radiofrequency energy to specific nerves near the kidneys that can become overactive and cause high blood pressure. Approved for commercial use in more than 60 countries around the world, the Symplicity Spyral renal denervation system is limited to investigational use in the United States , Japan , and Canada .

About Medtronic
Bold thinking. Bolder actions. We are Medtronic. Medtronic plc, headquartered in Dublin, Ireland , is the leading global healthcare technology company that boldly attacks the most challenging health problems facing humanity by searching out and finding solutions. Our Mission — to alleviate pain, restore health, and extend life — unites a global team of 90,000+ passionate people across 150 countries. Our technologies and therapies treat 70 health conditions and include cardiac devices, surgical robotics, insulin pumps, surgical tools, patient monitoring systems, and more. Powered by our diverse knowledge, insatiable curiosity, and desire to help all those who need it, we deliver innovative technologies that transform the lives of two people every second, every hour, every day. Expect more from us as we empower insight-driven care, experiences that put people first, and better outcomes for our world. In everything we do, we are engineering the extraordinary. For more information on Medtronic (NYSE:MDT), visit and follow @Medtronic on Twitter and LinkedIn .

Any forward-looking statements are subject to risks and uncertainties such as those described in Medtronic's periodic reports on file with the Securities and Exchange Commission. Actual results may differ materially from anticipated results.

1 Fatani N, Dixon DL, Van Tassell BW, Fanikos J, Buckley LF. Systolic Blood Pressure Time in Target Range and Cardiovascular Outcomes in Patients With Hypertension. Journal of the American College of Cardiology 2021;77:1290–1299.


Krystin Hayward Leong

Ryan Weispfenning

Public Relations

Investor Relations



(PRNewsfoto/Medtronic plc)

Cision View original content to download multimedia:

SOURCE Medtronic plc

Cision View original content to download multimedia:

News Provided by Canada Newswire via QuoteMedia

The Conversation (0)

PrairieSky Announces 2023 Second Quarter Results, Including Record Oil Royalty Production

PrairieSky Royalty Ltd. (" PrairieSky " or the " Company ") (TSX: PSK) is pleased to announce its second quarter (" Q2 2023 ") results for the three-month period ended June 30, 2023.

Second Quarter Highlights:

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

Nanalysis To Be Featured on Radius Research's Pitch, Deep Dive and Q&A Webinar

Webinar tomorrow Weds, June 21st at 2:00pm ET / 11AM MDT

Nanalysis Scientific Corp. ("the Company") (TSXV: NSCI) (OTCQX: NSCIF) (FRA: 1N1), a leader in portable NMR machines and MRI technology for industrial and research applications is pleased to invite investors and other interested parties to attend an upcoming interview with Market Radius Research. Martin Gagel of Market Radius Research and CEO Sean Krakiwsky and CFO Randall McRae are providing an update and outlook on Nanalysis' growth and opportunities.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less

Nanalysis Announces Annual General Meeting

Meeting to Be Held on Wednesday, June 28th at 9:00 AM MDT

Nanalysis Scientific Corp. ("the Company", TSXV: NSCI OTCQX: NSCIF FRA: 1N1 ), a leader in portable NMR machines and MRI technology for industrial and research applications, announces that the Annual General Meeting (AGM) will take place on Wednesday June 28, 2023 at 9 AM MDT at Bay 1, 4600 5 th Street NE, Calgary, Alberta T2E 7C3.  Following the formal part of the meeting, Sean Krakiwsky President and Chief Executive Officer of the Corporation, will provide a corporate presentation.

News Provided by Canada Newswire via QuoteMedia

Keep reading...Show less
Canadian Natural Resources Limited Announces 2023 First Quarter Results

Canadian Natural Resources Limited Announces 2023 First Quarter Results

Commenting on the Company's first quarter 2023 results, Tim McKay, President of Canadian Natural Resources Limited (TSX: CNQ) (NYSE: CNQ), stated, "Canadian Natural delivered strong results in Q123 with effective and efficient operations on our balanced and diverse portfolio of high quality assets. Our culture of continuous improvement, focus on cost control and disciplined capital allocation continues to drive strong financial results and maximize value for our shareholders. In Q123, we delivered total quarterly production of approximately 1,319 MBOE‍‍d, including record natural gas production of 2,139 MMcfd and liquids production of 962,908 bbl‍d. We generated strong quarterly free cash flow of approximately $1.4 billion, after dividends of approximately $0.9 billion and net base capital expenditures of approximately $1.1 billion. In addition, our strategic growth capital expenditures of approximately $0.28 billion in the quarter was targeted to provide mid-term growth across our asset base as we unlock value from our projects with strong capital efficiencies. With ample liquidity on our balance sheet, we can add production with minimal capital while generating significant returns on capital and maximizing shareholder value.

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet and Market-Leading U.S. Uranium & Rare Earth Positions

Energy Fuels Announces Q2-2022 Results, Including Continued Robust Balance Sheet and Market-Leading U.S. Uranium & Rare Earth Positions

Webcast on August 9, 2022

Energy Fuels Inc. (NYSE: UUUU) (TSX: EFR) ("Energy Fuels" or the "Company") today reported its financial results for the quarter ended June 30, 2022 . The Company's quarterly report on Form 10-Q has been filed with the U.S. Securities and Exchange Commission (" SEC ") and may be viewed on the Electronic Document Gathering and Retrieval System (" EDGAR ") at www.sec.govedgar.shtml on the System for Electronic Document Analysis and Retrieval (" SEDAR ") at and on the Company's website at . Unless noted otherwise, all dollar amounts are in U.S. dollars.

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
Ocumetics Technology

Ocumetics Technology

Keep reading...Show less

League of United Latin American Citizens Joins OraPharma in the Fight Against Gum Disease

Partnership Aims to Educate Hispanic Communities About the Signs, Symptoms, and Prevalence of Gum Disease

Collaboration Launches During Hispanic Heritage Month With Activations Featuring Patient Ambassador Alex Rodriguez

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Medtronic Diabetes announces CE Mark for new Simplera CGM with disposable all-in-one design

The company's newest Simplera™ CGM is 50% smaller than its previous generation with a simple insertion and improved user experience

Medtronic plc (NYSE:MDT), a global leader in healthcare technology, today announced CE (Conformité Européenne) Mark approval for its new all-in-one, disposable Simplera™ continuous glucose monitor (CGM) featuring a simple, two-step insertion process. The company's newest no-fingerstick sensor does not require over tape and is seamlessly integrated with the InPen™ smart insulin pen, which provides real-time, personalized dosing guidance to help simplify diabetes management. Medtronic will begin a phased launch at the European Association for the Study of Diabetes (EASD) 59th Annual Meeting in Hamburg, Germany on Oct. 2-6, 2023 .

News Provided by PR Newswire via QuoteMedia

Keep reading...Show less
closeup of stethoscope

What Do Medical Device Companies Do? (Updated 2023)

Medical device companies play a vital role in the life science industry by developing new technologies to match unmet medical needs across both established and emerging healthcare markets.

The growing prevalence of chronic diseases such as cancer and diabetes is the driving force behind increasing innovation in medical technology, from surgical instruments and orthopedics to diagnostics and medical imaging.

In 2022, 41 new medical devices were approved by the US Food and Drug Administration (FDA), a big jump from the 28 approved in 2021. The agency attributed 2021's low numbers to employee burnout and a strain on resources after a hectic 2020 responding to the COVID-19 pandemic. 2023 is shaping up to be another good year for medical device approvals, with 35 already in the books as of mid-September. However, the final tally is not expected to reach the 63 approvals set in 2020.

Keep reading...Show less

Medtronic LABS Unveils Commitment To Scale Tech-Enabled Healthcare at Clinton Global Initiative 2023 Meeting

The commitment will form a consortium that brings together cross-sector partners to scale community-based, tech-enabled solutions for underserved patients, families, and communities across the world.

At Medtronic LABS, we're working every day to cultivate a bolder, more equitable, and outcomes-focused global health system for the future. This week, we announced a Commitment to Action to scale tech-enabled healthcare at the Clinton Global Initiative 2023 meeting

News Provided by ACCESSWIRE via QuoteMedia

Keep reading...Show less

Latest Press Releases

Related News